Paper29428486
Intra-articular knee implantation of autologous bone marrow-derived mesenchymal stromal cells in rheumatoid arthritis patients with knee involvement: Results of a randomized, triple-blind, placebo-controlled phase 1/2 clinical trial.
Shadmanfar S and 13 others. Cytotherapy, 2018. Cited by 81 papers, by iCite.
Cite this record
ConductScience Library. Intra-articular knee implantation of autologous bone marrow-derived mesenchymal stromal cells in rheumatoid arthritis patients with knee involvement: Results of a randomized, triple-blind, placebo-controlled phase 1/2 clinical trial. Papers, record 29428486. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/29428486
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
Intra-articular knee implantation of autologous bone marrow-derived mesenchymal stromal cells in rheumatoid arthritis patients with knee involvement: Results of a randomized, triple-blind, placebo-controlled phase 1/2 clinical trial.
- PubMed
- Publication types
- Clinical Trial, Phase I, Clinical Trial, Phase II, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- PubMed
Topics17
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Arthritis, Rheumatoid | Major topic |
| Bone Marrow Cells | Major topic |
| Bone Marrow Transplantation | Major topic |
| Mesenchymal Stem Cell Transplantation | Major topic |
| Mesenchymal Stem Cells | Major topic |
| Osteoarthritis, Knee | Major topic |
| Adult | |
| Aged | |
| Double-Blind Method | |
| Female | |
| Humans | |
| Injections, Intra-Articular | |
| Knee Joint | |
| Male | |
| Middle Aged | |
| Placebos | |
| Treatment Outcome |
Source PubMed
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT01873625 | Transplantation of Bone Marrow Derived Mesenchymal Stem Cells in Affected Knee Osteoarthritis by Rheumatoid Arthritis | Derived from the trial | Yes |
Source ClinicalTrials.gov
Cited by58
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 81 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42808120 | Immunomodulatory Properties of Mesenchymal Stem Cells and Their Extracellular Vesicles: Potential Clinical Applications in Autoimmune Diseases. | Cureus | 2026 | https://conductscience.org/library/papers/42808120 | PubMed |
| 42523644 | Systemic regulation of rheumatoid arthritis by mesenchymal stem cells: from immune homeostasis to microbiota modulation. | Front Immunol | 2026 | https://conductscience.org/library/papers/42523644 | PubMed |
| 42038136 | The Role of Mesenchymal Stem/Stromal Cells and Their Extracellular Vesicles in Rheumatoid Arthritis. | Galen Med J | 2024 | https://conductscience.org/library/papers/42038136 | PubMed |
| 41782044 | Quantitative evaluation of mesenchymal stromal cell immunomodulatory potency and cost-effectiveness of cytokine licensing for translational application. | J Transl Med | 2026 | https://conductscience.org/library/papers/41782044 | PubMed |
| 41640457 | Stem Cell Therapy for Inflammatory Diseases: Progress, Challenges, and Future Directions. | MedComm (2020) | 2026 | https://conductscience.org/library/papers/41640457 | PubMed |
| 41398594 | Hierarchical therapeutic potential in the mesenchymal stem cell landscape. | J Transl Med | 2025 | https://conductscience.org/library/papers/41398594 | PubMed |
| 41310172 | Engineering CCR2/IFN-γ overexpression in enucleated mesenchymal stem cells enhances therapy for rheumatoid arthritis. | Commun Biol | 2025 | https://conductscience.org/library/papers/41310172 | PubMed |
| 40740529 | Molecular and therapeutic effects of mesenchymal stem cell-derived exosomes on autoimmune diseases. | World J Stem Cells | 2025 | https://conductscience.org/library/papers/40740529 | PubMed |
| 40671080 | Harnessing mesenchymal stem/stromal cells-based therapies for rheumatoid arthritis: mechanisms, clinical applications, and microenvironmental interactions. | Stem Cell Res Ther | 2025 | https://conductscience.org/library/papers/40671080 | PubMed |
| 40565230 | Advances in Regenerative Therapies for Inflammatory Arthritis: Exploring the Potential of Mesenchymal Stem Cells and Extracellular Vesicles. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/40565230 | PubMed |
| 40525425 | Modulating Proliferation, Migration and Differentiation of Mesenchymal Stem Cells Using Interleukins. | Curr Stem Cell Res Ther | 2025 | https://conductscience.org/library/papers/40525425 | PubMed |
| 39987230 | Human nasal turbinate stem cells with specific gene signatures (HAS2, CXCL1, KRTAP1-5, GSTT2B, and C4B) attenuate rheumatoid arthritis. | Sci Rep | 2025 | https://conductscience.org/library/papers/39987230 | PubMed |
| 39934871 | Efficacy and safety of mesenchymal stromal cell transplantation in the treatment of autoimmune and rheumatic immune diseases: a systematic review and meta-analysis of randomized controlled trials. | Stem Cell Res Ther | 2025 | https://conductscience.org/library/papers/39934871 | PubMed |
| 39767754 | Extracellular Vesicles from Mesenchymal Stem Cells: Potential as Therapeutics in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). | Biomedicines | 2024 | https://conductscience.org/library/papers/39767754 | PubMed |
| 39360004 | Advanced therapy with mesenchymal stromal cells for knee osteoarthritis: Systematic review and meta-analysis of randomized controlled trials. | J Orthop Translat | 2024 | https://conductscience.org/library/papers/39360004 | PubMed |
| 39239074 | Combination treatment with interferon-γ may be a potential strategy to improve the efficacy of cytotherapy for rheumatoid arthritis: A network meta-analysis. | J Res Med Sci | 2024 | https://conductscience.org/library/papers/39239074 | PubMed |
| 39120313 | Cell-Based Therapy and Genome Editing as Emerging Therapeutic Approaches to Treat Rheumatoid Arthritis. | Cells | 2024 | https://conductscience.org/library/papers/39120313 | PubMed |
| 39026275 | Adipose-derived mesenchymal stem cell therapy for connective tissue diseases and complications. | Inflamm Regen | 2024 | https://conductscience.org/library/papers/39026275 | PubMed |
| 38477559 | Mesenchymal Stem Cells-Involved Strategies for Rheumatoid Arthritis Therapy. | Adv Sci (Weinh) | 2024 | https://conductscience.org/library/papers/38477559 | PubMed |
| 38366909 | A Phase I Dose-Escalation Clinical Trial to Assess the Safety and Efficacy of Umbilical Cord-Derived Mesenchymal Stromal Cells in Knee Osteoarthritis. | Stem Cells Transl Med | 2024 | https://conductscience.org/library/papers/38366909 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/29428486
GET https://conductscience.org/api/papers/v1/29428486/cited_by?page=2